Alpha-linolenic Acid and Blood Pressure

Hypertension Clinical Trial

— VASALA  

Official title:

Effects of Alpha-linolenic Acid on 24h-ambulatory Mean Arterial Pressure in Untreated High-normal and Stage I Hypertensive Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02243969
• Other study ID #: MEC 13-3-064
• Status: Completed
• Phase: N/A
• First received: May 19, 2014
• Last updated: March 21, 2016
• Start date: May 2014
• Est. completion date: October 2015

Study information

• Verified date: September 2015
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)
• Study type: Interventional

Clinical Trial Summary

Rationale: Increased intakes of n-3 long chain polyunsaturated fatty acids eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA), mainly found in fatty fish, are recommended for the prevention of coronary heart disease. Alpha-linolenic acid (ALA, C18:3n-3) is the most common vegetable-oil based n-3 fatty acid. Evidence exists that ALA supplementation can also have a protective effect on the development on cardiovascular disease, but may exert its cardio protective effects through different routes. The benefit may (partly) be due to blood pressure lowering. However, evidence for beneficial effects of ALA on blood pressure is conflicting. Therefore, we propose to investigate the effect of flaxseed oil, high in ALA, using a study powered on 24-hour blood pressure, in a population with high normal blood pressure and mild hypertension.

Objective: To study the effects of flaxseed oil, rich in ALA on 24h-ambulatory mean arterial pressure (MAP) in men and women with high-normal blood pressure and mild hypertension compared to high oleic sunflower oil, poor in ALA.

Study design: Using a double blind randomized, placebo-controlled parallel design, subjects will receive at random daily 10 g of flaxseed oil or a high-oleic acid sunflower oil (HOSF) as control for twelve weeks, with a run-in period of 14 days in advance.

Study population: 72 men and women, aged 40-70 years, with untreated high-normal blood pressure and stage I hypertension and a body mass index between 25 and 35 kg/m2 will participate in the run-in and intervention period. It is estimated that 144 subject have to be screened to find 72 subjects that will enter the run-in period.

Intervention: During the run-in period, subjects will receive daily 10 g of palm super olein oil. During the intervention period subjects receive either 10 g of HOSF or flaxseed oil. All oils are provided in bottles of 5 g, one will be consumed at breakfast or lunch and one at dinner.

Main study parameters/endpoints: The main study parameter is the change in 24h-ambulatory mean arterial pressure (MAP)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

• Quetelet-index between 25-35 kg/m2

• High-normal blood pressure defined as systolic blood pressure between 130-139 mmHg and/or diastolic blood pressure between 85-89 mmHg. Or stage I hypertension defined as systolic blood pressure between 140-159 mmHg and/or diastolic blood pressure between 90-99 mmHg.

• Mean serum total cholesterol/HDL cholesterol ratio < 8

• Mean serum triacylglycerol < 4.5 mmol/L

• Mean plasma glucose < 7.0 mmol/L

Exclusion Criteria:

• Unstable body weight (weight gain or loss >2 kg in the past 3 months)

• Use of antihypertensive or anticoagulant medication

• Indication for treatment with medication according to the Standard for cardiovascular risk management of the Dutch general practitioners community (NHG)

• Usage of non-steroidal anti-inflammatory drugs (such as aspirin, ibuprofen, naproxen) and not able or willing to stop taking them from at least 4 weeks prior to the study

• Use of medication or a diet known to affect serum lipid or glucose metabolism

• Women with expected changes in the use of oral contraceptives or estrogen replacement therapy during the study period

• Women lactating, pregnant or intend to become pregnant during study

• Active cardiovascular disease like congestive heart failure or recent (<6 months) event (acute myocardial infarction, cerebro vascular accident)

• Severe medical conditions that might interfere with the study such as diabetes mellitus, epilepsy, asthma, chronic obstructive pulmonary disease, inflammatory bowel diseases and rheumatoid arthritis

• Smoking or recently quit smoking (<1 years)

• Abuse of drugs

• More than 21 alcohol consumptions per week for men and 14 consumptions for women

• Reported intense sporting activities > 10 h/w

• Not possible or difficult to venipuncture as evidenced during the screening visits

• Use of an investigational product within the previous 30 days

• Not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study

• Not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Hypertension
• Lipid Metabolism Disorders
• Metabolic Diseases

Intervention

Dietary Supplement:
• Flaxseed oil
The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
• high oleic sunflower oil (HOSF)
The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Center	Maastricht	Limburg

Sponsors (2)

Lead Sponsor	Collaborator
Maastricht University Medical Center	Unilever R&D

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pulse wave velocity (PWV)	PWV will be determined by extending data from standard brachial artery blood pressure measurements	Baseline and end of intervention period (week 2 and 14)	No
Other	Retinal microvasculature	Measured as AV-ratio and vessel diameter from digitized analogue fundus photographs	Baseline and end of intervention period (week 2 and 14)	No
Other	Fasting and postprandial lipid and glucose metabolism	Postprandial glucose at time point 15,30,45,60,90,120,180,240 minutes Postprandial lipids at time point 60, 120, 180, 240 minutes	Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group	No
Other	Fasting and postprandial serum biomarkers for low-grade systemic inflammation (hsCRP, IL-6) and endothelial function (sICAM-1, VCAM-1, MCP-1 and sE-Selectin)		Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group at time point 60, 120, 240 minutes	No
Primary	24h-ambulatory mean arterial pressure (MAP)	Ambulatory blood pressure measurements will be performed using an automated blood pressure device with 15-minute intervals during the day and 30-minute intervals during the night.	Baseline and end of intervention period (week 2 and 14)	No
Secondary	Postprandial flow mediated dilatation (FMD)	The brachial artery FMD will be measured in a subset (n=20 per group) of the study population. FMD will be measured before and 2 hours after a fat load.	End of intervention period (week 14)	No
Secondary	Night, day and early morning 24h-ambulatory MAP, SBP and DBP	Ambulatory blood pressure measurements will be performed using an automated blood pressure device with 15-minute intervals during the day and 30-minute intervals during the night.	Baseline and end of intervention (week 2 and 14)	No
Secondary	Systolic, diastolic and MAP office blood pressure	Each visit blood pressure will be measured in four-fold with 1-minute interval (the first measurement will be discarded and the last three measurement will be averaged) using a calibrated device.	Measured every visit (week 1,2,8,14)	No
Secondary	The fatty-acid profile of plasma phospholipids	measured in fasting plasma samples	Baseline and end of intervention period (week 2 and 14)	No